Age Patterns of HSV-2 Incidence and Prevalence in Two Ugandan Communities: A Catalytic Incidence Model Applied to Population-Based Seroprevalence Data.

Author(s): Whittles LK, Galiwango RM, Mpagazi J, Tobian AAR, Ssekubugu R, Jackson J, Peer AD, Kennedy C, Nakalanzi M, Ndyanabo A, Kigozi G, Chang LW, Serwadda D, Manabe YC, Gaydos CA, Laeyendecker O, Quinn TC, Reynolds SJ, Kagaayi J, Eaton JW, Grabowski MKJournal: J Infect DisPMID: 37079374 November 2023
Herpes simplex virus type 2 (HSV-2) is an incurable sexually transmitted infection associated with increased risk of acquiring and transmitting…

Whole-Genome Sequencing to Predict Antimicrobial Susceptibility Profiles in Neisseria gonorrhoeae.

Author(s): Bristow CC, Mortimer TD, Morris S, Grad YH, Soge OO, Wakatake E, Pascual R, Murphy SM, Fryling KE, Adamson PC, Dillon JA, Parmar NR, Le HHL, Van Le H, Ovalles Ureña RM, Mitchev N, Mlisana K, Wi T, Dickson SP, Klausner JDJournal: J Infect DisPMID: 36735316 April 2023
Neisseria gonorrhoeae is a major public health problem due to increasing incidence and antimicrobial resistance. Genetic markers of reduced susceptibility…

Reply to Hasford and to Spinola et al.

Author(s): Eyal N, Lipsitch M, Smith PGJournal: J Infect DisPMID: 32845306 August 2020
We proposed human challenge trials (HCTs) as a possible alternative or complement to conventional phase 3 trials for expedited severe…

Response to Cioffi.

Author(s): Eyal N, Lipsitch M, Smith PGJournal: J Infect DisPMID: 32348499 June 2020
Dr Cioffi rails against our comparison of human challenge studies to organ donation, but the risk of donor death from…

Response to Dawson et al.

Author(s): Eyal N, Lipsitch M, Smith PGJournal: J Infect DisPMID: 32495823 June 2020
Dawson et al raise three concerns about human challenge trials to assess the efficacy of SARS-CoV-2 vaccines. First, that current…